EvoNext Holdings SA

EvoNext Holdings SA

BBX:ADF0
2.13
CHF
-0.04
(-1.75%)
5.50MMarket Cap
Feb 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.55
6.66
5.58
4.6
3.55
2.9
3.76
2.4
2.81
3.63
1.75
- -
- -
- -
Basic EPS, GAAP
-13.65
-15.33
-18.93
-18.92
-20.21
-9.48
-7.02
-9.49
-11.72
-10.13
-19.5
0.14
-0.09
- -
Free Cash Flow per Basic Share
-11.72
-15.18
-19.94
-18.41
-18.75
-11.85
-6.34
-9.2
-9.54
-4.94
-1.8
-0.34
-0.16
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
66.97
105.43
107.4
90.9
73.4
63.01
55.64
44.96
33.07
23.78
0.77
0.91
0.82
0.82
Tangible Book Value per Share
14.41
22.57
37.11
21.71
32
17.96
12.45
6.57
4.63
3.04
0.77
0.91
0.82
0.82
Basic Weighted Avg Shares
1
1
2
2
2
3
3
3
4
4
5
7
7
7
Sales/Revenue/Turnover
9
9
9
9
7
9
12
8
10
16
9
- -
- -
- -
Operating Margin (%)
-203.16
-265.21
-422.26
-480.09
-655.79
-344.09
-173.57
-330.27
-425.5
-259.93
-533.65
- -
- -
- -
Depreciation Expense
3
4
7
7
5
5
8
8
9
8
5
- -
- -
- -
Net Income, GAAP
-16
-21
-32
-36
-39
-29
-22
-30
-41
-43
-105
1
-1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-180.7
-230.03
-339.29
-411.2
-569.28
-327.05
-186.61
-396.12
-417.78
-279.07
-1,114.98
- -
- -
- -
Working Capital
22
49
81
51
95
52
36
18
18
11
7
7
6
6
LT Debt
3
4
4
4
2
2
5
4
4
3
- -
- -
- -
- -
Total Equity
83
175
203
173
221
194
173
145
132
106
6
7
6
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12.98
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.25
- -
- -
Return on Common Equity (%)
-22.28
-16.82
-17.02
-19.3
-19.89
-14.08
-11.8
-18.81
-29.81
-36.44
-188.26
17.18
-10.41
- -

Capital Structure

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
6
8
6

Working Capital

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
8
7
7
Cash, Cash Equivalents & STI
7
6
6
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-14.09%
-22.89%
-9.9%
Free Cash Flow
-19.29%
-40.64%
-53.14%
Net Income, GAAP
-6.94%
-15.53%
-162.53%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
9
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-19.5
2024
- -
- -
0.14
2025
- -
- -
-0.09

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

CEO
Gerhard Lobmaier
Full Time Employees
49
Sector
Consumer non-durables
Industry
Food: specialty/candy
Address
Angensteinerstrasse 6 Reinach BL Switzerland 4153
IPO Date
May 4, 2005
Business
Evolva Holding S.A. (Ticker: ELVAF) develops and commercializes sustainable ingredients using proprietary biotechnology processes for the flavor, fragrance, cosmetics, and life sciences industries. The company offers a portfolio of nature-identical ingredients, including Valencene for nootkatone production, nootkatone as a natural insect repellent and flavor compound, sclareol for fragrance applications, and specialty biotech-derived products such as resveratrol, vanillin alternatives, and saffron components; these are produced via fermentation technology that enables scalable, environmentally friendly manufacturing without reliance on traditional plant extraction or chemical synthesis. Evolva serves customers in food and beverage, personal care, consumer health, and pharmaceutical sectors, with operations spanning Europe, North America, and Asia. Founded in 2004 and headquartered in Reinach, Switzerland, the company focuses on high-value, biotech-enabled molecules targeting premium markets demanding natural and sustainable solutions. In recent developments, Evolva has pursued strategic expansions in its nootkatone platform through partnerships for commercial scaling and continued advancements in its fermentation technology suite to broaden ingredient offerings amid growing demand for biotech flavors and repellents.